Treatment of cervical dystonia with botulinum toxin
Identifieur interne : 000D34 ( Istex/Corpus ); précédent : 000D33; suivant : 000D35Treatment of cervical dystonia with botulinum toxin
Auteurs : Joseph JankovicSource :
- Movement Disorders [ 0885-3185 ] ; 2004-03.
English descriptors
- KwdEn :
Abstract
Cervical dystonia (CD) is the most common form of dystonia encountered in a movement disorders clinic. The treatment of this focal dystonia has improved markedly with the advent on botulinum toxin (BTX) injections, which has now become the treatment of choice. Initial studies, even double‐blind controlled trials, failed to show robust effect, largely as a result of poor design, often using fixed dosage and site of administration. When the BTX treatment is customized to the needs of the individual patients and the most involved muscles are targeted, the effects can be quite dramatic and the improvement usually lasts 3 to 4 months. Experience and improved skills can largely prevent the adverse effects such as dysphagia and neck weakness. Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long‐term complications of CD, such as contractures and radiculopathy, have been largely eliminated. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20024
Links to Exploration step
ISTEX:A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of cervical dystonia with botulinum toxin</title><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><mods:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20024</idno><idno type="url">https://api.istex.fr/document/A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000D34</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of cervical dystonia with botulinum toxin</title><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><mods:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-03">2004-03</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">S8</biblScope><biblScope unit="page" from="S109">S109</biblScope><biblScope unit="page" to="S115">S115</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C</idno><idno type="DOI">10.1002/mds.20024</idno><idno type="ArticleID">MDS20024</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>botulinum toxin</term><term>cervical dystonia</term><term>dystonia</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cervical dystonia (CD) is the most common form of dystonia encountered in a movement disorders clinic. The treatment of this focal dystonia has improved markedly with the advent on botulinum toxin (BTX) injections, which has now become the treatment of choice. Initial studies, even double‐blind controlled trials, failed to show robust effect, largely as a result of poor design, often using fixed dosage and site of administration. When the BTX treatment is customized to the needs of the individual patients and the most involved muscles are targeted, the effects can be quite dramatic and the improvement usually lasts 3 to 4 months. Experience and improved skills can largely prevent the adverse effects such as dysphagia and neck weakness. Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long‐term complications of CD, such as contractures and radiculopathy, have been largely eliminated. © 2004 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Joseph Jankovic MD</name><affiliations><json:string>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>cervical dystonia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dystonia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>botulinum toxin</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Cervical dystonia (CD) is the most common form of dystonia encountered in a movement disorders clinic. The treatment of this focal dystonia has improved markedly with the advent on botulinum toxin (BTX) injections, which has now become the treatment of choice. Initial studies, even double‐blind controlled trials, failed to show robust effect, largely as a result of poor design, often using fixed dosage and site of administration. When the BTX treatment is customized to the needs of the individual patients and the most involved muscles are targeted, the effects can be quite dramatic and the improvement usually lasts 3 to 4 months. Experience and improved skills can largely prevent the adverse effects such as dysphagia and neck weakness. Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long‐term complications of CD, such as contractures and radiculopathy, have been largely eliminated. © 2004 Movement Disorder Society</abstract><qualityIndicators><score>6.841</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1012</abstractCharCount><pdfWordCount>4921</pdfWordCount><pdfCharCount>31375</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>160</abstractWordCount></qualityIndicators><title>Treatment of cervical dystonia with botulinum toxin</title><genre><json:string>Serial article</json:string></genre><host><volume>19</volume><pages><total>7</total><last>S115</last><first>S109</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S8</issue><author><json:item><name>Hans Bigalke</name></json:item><json:item><name>Dirk Dressler</name></json:item><json:item><name>Joseph Jankovic</name></json:item></author><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1002/mds.20024</json:string></doi><id>A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Treatment of cervical dystonia with botulinum toxin</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2004</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Treatment of cervical dystonia with botulinum toxin</title><author><persName><forename type="first">Joseph</forename><surname>Jankovic</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Parkinson's Disease Center, Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, 1801, Houston, TX 77030</p></note><affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-03"></date><biblScope unit="vol">19</biblScope><biblScope unit="issue">S8</biblScope><biblScope unit="page" from="S109">S109</biblScope><biblScope unit="page" to="S115">S115</biblScope></imprint></monogr><idno type="istex">A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C</idno><idno type="DOI">10.1002/mds.20024</idno><idno type="ArticleID">MDS20024</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2004</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Cervical dystonia (CD) is the most common form of dystonia encountered in a movement disorders clinic. The treatment of this focal dystonia has improved markedly with the advent on botulinum toxin (BTX) injections, which has now become the treatment of choice. Initial studies, even double‐blind controlled trials, failed to show robust effect, largely as a result of poor design, often using fixed dosage and site of administration. When the BTX treatment is customized to the needs of the individual patients and the most involved muscles are targeted, the effects can be quite dramatic and the improvement usually lasts 3 to 4 months. Experience and improved skills can largely prevent the adverse effects such as dysphagia and neck weakness. Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long‐term complications of CD, such as contractures and radiculopathy, have been largely eliminated. © 2004 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>cervical dystonia</term></item><item><term>dystonia</term></item><item><term>botulinum toxin</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="15"><doi origin="wiley" registered="yes">10.1002/mds.v19:8+</doi><titleGroup><title type="specialIssueTitle">Basic and Therapeutic Aspects of Neurotoxins</title></titleGroup><numberingGroup><numbering type="journalVolume" number="19">19</numbering><numbering type="journalIssue">S8</numbering></numberingGroup><creators><creator xml:id="sped1" creatorRole="sponsoringEditor"><personName><givenNames>Hans</givenNames><familyName>Bigalke</familyName></personName></creator><creator xml:id="sped2" creatorRole="sponsoringEditor"><personName><givenNames>Dirk</givenNames><familyName>Dressler</familyName></personName></creator><creator xml:id="sped3" creatorRole="sponsoringEditor"><personName><givenNames>Joseph</givenNames><familyName>Jankovic</familyName></personName></creator></creators><coverDate startDate="2004-03">March 2004</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="16" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20024</doi><idGroup><id type="unit" value="MDS20024"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2004 Movement Disorder Society</copyright><eventGroup><event type="firstOnline" date="2004-03-09"></event><event type="publishedOnlineFinalForm" date="2004-03-09"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">S109</numbering><numbering type="pageLast">S115</numbering></numberingGroup><correspondenceTo>Parkinson's Disease Center, Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, 1801, Houston, TX 77030</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20024.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="74"></count><count type="wordTotal" number="5413"></count></countGroup><titleGroup><title type="main" xml:lang="en">Treatment of cervical dystonia with botulinum toxin</title><title type="short" xml:lang="en">Treatment of Cervical Dystonia with BTX</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Joseph</givenNames><familyName>Jankovic</familyName><degrees>MD</degrees></personName><contactDetails><email>josephj@bcm.tmc.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">cervical dystonia</keyword><keyword xml:id="kwd2">dystonia</keyword><keyword xml:id="kwd3">botulinum toxin</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Cervical dystonia (CD) is the most common form of dystonia encountered in a movement disorders clinic. The treatment of this focal dystonia has improved markedly with the advent on botulinum toxin (BTX) injections, which has now become the treatment of choice. Initial studies, even double‐blind controlled trials, failed to show robust effect, largely as a result of poor design, often using fixed dosage and site of administration. When the BTX treatment is customized to the needs of the individual patients and the most involved muscles are targeted, the effects can be quite dramatic and the improvement usually lasts 3 to 4 months. Experience and improved skills can largely prevent the adverse effects such as dysphagia and neck weakness. Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long‐term complications of CD, such as contractures and radiculopathy, have been largely eliminated. © 2004 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Treatment of cervical dystonia with botulinum toxin</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Treatment of Cervical Dystonia with BTX</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Treatment of cervical dystonia with botulinum toxin</title></titleInfo><name type="personal"><namePart type="given">Joseph</namePart><namePart type="family">Jankovic</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</affiliation><description>Correspondence: Parkinson's Disease Center, Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, 1801, Houston, TX 77030</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2004-03</dateIssued><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">74</extent><extent unit="words">5413</extent></physicalDescription><abstract lang="en">Cervical dystonia (CD) is the most common form of dystonia encountered in a movement disorders clinic. The treatment of this focal dystonia has improved markedly with the advent on botulinum toxin (BTX) injections, which has now become the treatment of choice. Initial studies, even double‐blind controlled trials, failed to show robust effect, largely as a result of poor design, often using fixed dosage and site of administration. When the BTX treatment is customized to the needs of the individual patients and the most involved muscles are targeted, the effects can be quite dramatic and the improvement usually lasts 3 to 4 months. Experience and improved skills can largely prevent the adverse effects such as dysphagia and neck weakness. Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long‐term complications of CD, such as contractures and radiculopathy, have been largely eliminated. © 2004 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>cervical dystonia</topic><topic>dystonia</topic><topic>botulinum toxin</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><name type="personal"><namePart type="given">Hans</namePart><namePart type="family">Bigalke</namePart></name><name type="personal"><namePart type="given">Dirk</namePart><namePart type="family">Dressler</namePart></name><name type="personal"><namePart type="given">Joseph</namePart><namePart type="family">Jankovic</namePart></name><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2004</date><detail type="title"><title>Basic and Therapeutic Aspects of Neurotoxins</title></detail><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>S8</number></detail><extent unit="pages"><start>S109</start><end>S115</end><total>7</total></extent></part></relatedItem><identifier type="istex">A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C</identifier><identifier type="DOI">10.1002/mds.20024</identifier><identifier type="ArticleID">MDS20024</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2004 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D34 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000D34 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C
|texte= Treatment of cervical dystonia with botulinum toxin
}}
| This area was generated with Dilib version V0.6.23. |  |